Outcome of immunization of cynomolgus monkeys with recombinant semliki forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus

AIDS Research and Human Retroviruses

Volumn 13, Issue 17, 1997, Pages 1487-1495

  Berglund, Peter ^a   Quesada Rolander, Marlene ^b   Putkonen, Per ^b   Biberfeld, Gunnel ^b   Thorstensson, Rigmor ^b   Liljeström, Peter ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 160; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHIMERA; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LYMPHOCYTE PROLIFERATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEMLIKI FOREST ALPHAVIRUS; VACCINATION; VIRUS DETECTION; VIRUS ISOLATION;

EID: 0030813127     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1997.13.1487     Document Type: Article

References (66)

1. Girard M, Kieny M-P, Pinter A, Barré-Sinoussi F, Nara P, Kolbe H, Kusumi K, Chaput A, Reinhart T, Muchmore E, Ronco J, Kaczorek M, Gomard E, Gluckman J-C, and Fultz PN: Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proc Natl Acad Sci USA 1991;88: 542-546.
2. Berman PW, Gregory TJ, Riddle L, Nakamura GR, Champe MA, Porter JP, Wurm FM, Herschberg RD, Cobb EK, and Eichberg JW: Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature (London) 1990;345:622-625.
3. Nilsson C, Thorstensson R, Gilljam G, Sjölander S, Hild K, Broliden K, Åkerblom L, Morein B, Biberfeld G, and Putkonen P: Protection against monkey-cell grown cell-free HIV-2 challenge in macaques immunized with native HIV-2 envelope glycoprotein gp125. Vaccine Res 1995;4:165-175.
4. Putkonen P, Nilsson C, Walther L, Ghavamzadeh L, Hild K, Broliden K, Biberfeld G, and Thorstensson R: Efficacy of inactivated whole HIV-2 vaccines with various adjuvants in cynomolgus monkeys. J Med Primatol 1994;23:89-94.
5. Almond N, Kent K, Cranage M, Rud E, Clarke B, and Stott EJ: Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells. Lancet 1995;345:1342-1344.
6. Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, and Desrosiers RC: Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 1992;258:1938-1941.
7. Putkonen P, Walther L, Zhang Y-J, Li S-L, Nilsson C, Albert J, Biberfeld P, Thorstensson R, and Biberfeld G: Long-term protection agains SIV-induced disease in macaques vaccinated with a live attenuated HIV-2 vaccine. Nature Med 1995;1:914-918.
8. Putkonen P, Thorstensson R, Albert J, Hild K, Norrby E, Biberfeld P, and Biberfeld G: Infection of cynomolgus monkeys with HIV-2 protects against pathogenic consequences of a subsequent simian immunodeficiency virus infection. AIDS 1990;4:783-789.
9. Marthas M, Sujipto S, Higgins J, Lohman B, Torten J, Luciw PA, Marx PA, and Pedersen NC: Immunization with a live attenuated simian immunodeficiency virus (SIV) prevents early disease but not infection in rhesus macaques challenged with a pathogenic SIV. J Virol 1990;64:3694-3700.
10. Wyand MS, Manson KH, Garcia-Moll M, Montefiori D, and Desrosiers RC: Vaccine protection by a triple mutant of simian immunodeficiency virus. J Virol 1996;70:3724-3733.
11. Hirsch VM, Goldstein S, Hynes NA, Elkins WR, London WT, Zack PM, Montefiori D, and Johnson PR: Prolonged clinical latency and survival of macaques given a whole inactivated simian immunodeficiency virus vaccine. J Infect Dis 1994;170:51-59.
12. Shafferman A, Lewis MG, McCutchan FE, Benvenieste RE, Jahrling PB, Burke DS, and Eddy GA: Prevention of transmission of simian immunodeficiency virus from vaccinated macaques that developed transient virus infection following challenge. Vaccine 1993;11:848-852.
13. Shafferman A, Jahrling PB, Benvenieste RE, Lewis MG, Phipps TJ, McCutchan FE, Sadoff J, Eddy GA, and Burke DS: Protection of macaques with a simian immunodeficiency virus envelope peptide vaccine based on conserved human immunodeficiency 1 sequences. Proc Natl Acad Sci USA 1991;88:7126-7130.
14. Baba TW, Jeong YS, Penninck D, Bronson R, Greene MF, and Ruprecht RM: Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science 1995;267:1820-1825.
15. Moss B: Vaccinia virus vectors. Biotechnology 1992;20:345-362.
16. Ulaeto D and Hruby DE: Uses of vaccinia virus in vaccine delivery. Curr Opin Biotechnol 1994;5:501-504.
17. Tartaglia J, Perkus ME, Taylor J, Norton EK, Audonnet J-C, Cox WT, Davis SW, van der Hoeven J, Meignier B, Riviere M, Languet B, and Paoletti E: NYVAC: A highly attenuated strain of vaccinia virus. Virology 1992;188:217-232.
18. Sutter G and Moss B: Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci USA 1992; 89:10847-10851.
19. Cooney EL, McElrath MJ, Corey L, Hu S-L, Collier AC, Arditti D, Hoffman M, Coombs RW, Smith GE, and Greenberg PD: Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. Proc Natl Acad Sci USA 1993; 90:1882-1886.
20. Cooney EL, Collier AC, Greenberg PD, Coombs RW, Zarling J, Arditti DE, Hoffman MC, Hu S-L, and Corey L: Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet 1991;337:567-572.
21. Cox WI, Tartaglia J, and Paoletti E: Induction of cytotoxic T lymphocytes by recombinant canarypox (ALVAC) and attenuated vaccinia (NYVAC) viruses expressing the HIV-1 envelope glycoprotein. Virology 1993;195:845-850.
22. Shen L, Chen ZW, Miller MD, Stallard V, Mazzara GP, Panicali DL, and Letvin NL: Recombinant virus vaccine-induced SIV-specific CD8+ cytotoxic T lymphocytes. Science 1991;252:440-443.
23. Johnson RP, Hammond SA, Trocha A, Siliciano RF, and Walker BD: Induction of a major histocompatibility complex class I-restricted cytotoxic T-lymphocyte response to a highly conserved region of human immunodeficiency virus type 1 (HIV-1) gp120 in seronegative humans immunized with a candidate HIV-1 vaccine. J Virol 1994;68:3145-3153.
24. Sutter G, Wyatt LS, Foley PL, Bennick JR, and Moss B: A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 1994;12:53-59.
25. Benvenieste RE, Kuller L, Roodman ST, Hu S-L, and Morton WR: Long-term protection of macaques against high-dose type D retrovirus challenge after immunization with recombinant vaccinia virus expressing envelope glycoproteins. J Med Primatol 1993;22: 74-79.
26. Brody BA, Hunter E, Kluge JD, Lasarow R, Gardner M, and Marx PA: Protection of macaques against infection with simian type D retrovirus (SRV-1) by immunization with recombinant vaccinia virus expressing the envelope glycoproteins of either SRV-1 or Mason-Pfizer monkey virus (SRV-3). J Virol 1992;66:3950-3954.
27. Portetelle D, Limbach K, Burny A, Mammerickx M, Desmettre P, Riviere M, Zavada J, and Paoletti E: Recombinant vaccinia virus expression of the bovine leukaemia virus envelope gene and protection of immunized sheep against infection. Vaccine 1991; 9:194-200.
28. Hu S-L, Abrams K, Baber GN, Moran P, Zarling JM, Langlois AJ, Kuller L, Morton WR, and Benveniste RE: Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science 1992;255:456-459.
29. Hu SL, Abrams K, Misher L, Stallard V, Moran P, Zarling JM, Langlois AJ, Kuller L, Morton WR, and Benveniste RE: Evaluation of protective efficacy of recombinant subunit vaccines against simian immunodeficiency virus infection in macaques. J Med Primatol 1992;21:119-125.
30. Abimiku AG, Franchini G, Tartaglia J, Aldrich K, Myagkikh M, Markham PD, Chong P, Klein M, Kieny M-P, Paoletti E, Gallo RC, and Robert-Guroff M: HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques. Nature Med 1995;1:321-329.
31. Andersson S, Makitalo B, Thorstensson R, Franchini G, Tartaglia J, Limbach K, Paoletti E, Putkonen P, and Biberfeld G: Immunogenicity and protective efficacy of a human immunodeficiency virus type 2 recombinant canarypox (Alvac) vaccine candidate in cynomolgus monkeys. J Infect Dis 1996;174:977-985.
32. Ahmad S, Lohman B, Marthas M, Giavedoni L, El-Ahmad Z, Haigwood NL, Scandella CJ, Gardner MB, Luciw PA, and Yilma T: Reduced virus load in rhesus macaques immunized with recombinant gp160 and challenged with simian immunodeficiency virus. AIDS Res Hum Retroviruses 1994;10:195-204.
33. Israel ZR, Edmonson PF, Maul DH, O'Neil SP, Mossman SP, Thiriart C, Fabry L, van Opstal O, Bruck C, Bex F, Burny A, Fultz PN, Mullins JI, and Hoover EA: Incomplete protection, but suppression of virus burden, elicited by subunit simian immunodeficiency virus vaccines. J Virol 1994;68:1843-1853.
34. Giavedoni LD, Planelles V, Haigwood NL, Ahmad S, Kluge JD, Marthas ML, Gardner MB, Luciw PA, and Yilma TD: Immune response of rhesus macaques to recombinant simian immunodeficiency virus gp130 does not protect from challenge infection. J Virol 1993;67:577-583.
35. Berglund P, Sjöberg M, Atkins GJ, Sheahan BJ, Garoff H, and Liljeström P: Semliki Forest virus expression system: Production of conditionally infectious recombinant particles. Bio/Technology 1993;11:916-920.
36. Berglund P, Tubulekas I, and Liljeström P: Alphaviruses as vectors for gene delivery. Trends Biotechnol 1996;14:130-134.
37. Liljeström P and Garoff H: A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Bio/Technology 1991;9:1356-1361.
38. Liljeström P and Garoff H: Current Protocols in Molecular Biology. (Ausubel FM, Brent R, Kingston RE, Moore DD, Smith JA, Seidman JG, and Struhl K, eds.). Greene Publishing Associates and Wiley Interscience, New York, 1994, pp. 16.20.1-16.20.16.
39. Zhou X, Berglund P, Rhodes G, Parker SE, Jondal M, and Liljestrom P: Self-replicating Semliki Forest virus RNA as recombinant vaccine. Vaccine 1994;12:1510-1514.
40. Zhou X, Berglund P, Zhao H, Liljeström P, and Jondal M: Generation of cytotoxic and humoral immune responses using non-replicative recombinant Semliki Forest virus. Proc Natl Acad Sci USA 1995;92:3009-3013.
41. Mossman SP, Bex F, Berglund P, Arthos J, O'Neil SP, Riley D, Maul DH, Bruck C, Momin P, Burny A, Fultz PN, Mullins JI, Liljeström P, and Hoover EA: Protection against lethal simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccine. J Virol 1995;70:1953-1960.
42. Li J, Lord CI, Haseltine W, Letvin NL, and Sodroski J: Infection of cynomolgus monkeys with a chimeric HIV-1/SIVmac virus that expresses the HIV-1 envelope glycoproteins. J AIDS 1992;5: 639-646.
43. Paul NL, Marsh M, McKeating JA, Schulz TF, Liljeström P, Garoff H, and Weiss RA: Expression of HIV-1 envelope glycoproteins by Semliki Forest virus vectors. AIDS Res Hum Retroviruses 1993;9:963-970.
44. Salminen A, Wahlberg JM, Lobigs M, Liljeström P, and Garoff H: Membrane fusion process of Semliki Forest virus II: Cleavage dependent reorganization of the spike protein complex controls virus entry. J Cell Biol 1992;116:349-357.
45. Åkerblom L, Hinkula J, Broliden P-A, Mäkitalo B, Fridberger F, Rosen J, Villacres-Eriksson M, Morein B, and Wahren B: Neutralizing cross-reactive -and non-neutralizing monoclonal antibodies to HIV-1 gp120. AIDS 1990;4:953-960.
46. Gilljam G: Envelope glycoproteins of HIV-1, HIV-2 and SIV purified with Galantis nivalis agglutinin induce strong immune responses. AIDS Res Hum Retroviruses 1993;9:431-438.
47. Chiodi F, Bredberg-Rådén U, Biberfeld G, Böttiger B, Albert J, Åsjö B, Fenyö EM, and Norrby E: Radioimmunoprecipitation and Western blotting with sera of human immunodeficiency virus infected patients: A comparative study. AIDS Res Hum Retroviruses 1987;3:165-176.
48. mac). AIDS 1988;2:195-199.
49. Thorstensson R, Walther L, Putkonen P, Albert J, and Biberfeld G: A capture immunoassay for detection of HIV-2/SIV antigen. J AIDS 1991;4:374-379.
50. Li Y, Luo L, Thomas DY, and Kang CY: Control of expression, glycosylation, and secretion of HIV-1 gp120 by homologous and heterologous signal sequences. Virology 1994;204:266-278.
51. Hallenberger S, Bosch V, Angliker H, Shaw E, Klenk H-D, and Garten W: Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein gp160. Nature (London) 1992;360:358-361.
52. Hirsch VM, Fuerst TR, Sutter G, Carroll MW, Yang LC, Goldstein S, Piatak M, Elkins WR, Alvord WG, Montefiori DC, Moss B, and Lifson JD: Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: Effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. J Virol 1996;70:3741-3752.
53. Lu S, Arthos J, Montefiori DC, Yasutomi Y, Manson K, Mustafa F, Johnson E, Santoro JC, Wissink J, Mullins JI, Haynes JR, Letvin NL, Wyand M, and Robinson HL: Simian immunodeficiency virus DNA vaccine trial in macaques. J Virol 1996;70:3978-3991.
54. IIIB rgp120 subunit vaccine. Lancet 1993;342:69-73.
55. Keefer MC, Graham BS, McElrath MJ, Matthews TJ, Stablein DM, Corey L, Wright PF, Lawrence D, Fast PE, Weinhold K, Hsieh RH, Chernoff D, Dekker C, and Dolin R: Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group. AIDS Res Hum Retroviruses 1996;12:683-693.
56. Gorse GJ, Keefer MC, Belshe RB, Matthews TJ, Forrest BD, Hsieh RH, Koff WC, Hanson CV, Dolin R, Weinhold KJ, Frey SE, Ketter N, and Fast PE: A dose-ranging study of a prototype synthetic HIV-1MN V3 branched peptide vaccine. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J Infect Dis 1996;173:330-339.
57. Graham BS, Matthews TJ, Belshe RB, Clements ML, Dolin R, Wright PF, Gorse GJ, Schwartz DH, Keefer MC, Bolognesi DP, et al.: Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network. J Infect Dis 1993;167:533-537.
58. Borrow P, Lewicki H, Hahn BH, Shaw GM, and Oldstone MBA: Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994;68:6103-6110.
59. Salk J, Bretscher PA, Salk PL, Clerici M, and Shearer GM: A strategy for prophylactic vaccination against HIV. Science 1993;260:1270-1272.
60. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, Farthing C, and Ho DD: Temporal association of cellular immune response with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994;68: 4650-4655.
61. Trauger RJ, Giermakowska WK, Ferre F, Duffy PC, Wallace MR, Lewis DE, Beecham HJ, Burnett KG, Jensen FC, and Carlo DJ: Cell-mediated immunity to HIV-1 in Walter Reed stages 1-6 individuals: Correlation with virus burden. Immunology 1993;78: 611-615.
62. Rinaldo C, Huang X-L, Fan Z, Ding M, Beltz L, Logar A, Panicali D, Mazzara G, Liebmann J, Cottrill M, and Gupta P: High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term non-progressors. J Virol 1995;69:5838-5842.
63. Haynes BF, Pantaleo G, and Fauci AS: Toward an understanding of the correlates of protective immunity to HIV infection. Science 1996;271:324-328.
64. Lohman BL, McChesney MB, Miller CJ, McGowan E, Joye SM, Van Rompay KKA, Reay E, Antipa L, Pedersen NC, and Marthas ML: A partially attenuated simian immunodeficiency virus induces host immunity that correlates with resistance to pathogenic virus challenge. J Virol 1994;68:7021-7029.
65. Jurriaans S, Van Gemen B, Weverling GJ, Van Strijp D, Nara P, Coutinho R, Koot M, Schuilemaker H, and Goudsmit J: The natural history of HIV-1 infection: Virus load and virus phenotype independent determinants of clinical course? Virology 1994;204: 223-233.
66. Dickover RE, Dillon M, Collette SG, Deveikis A, Keller M, Plaeger-Marshall S, Chen I, Diagne A, Stiehm ER, and Bryson Y: Rapid increases in load of human immunodeficiency virus correlate with early progression and loss of CD4 cells in vertically infected infants. J Infect Dis 1994;170:1279-1284.